iShares Neuroscience ETF Gains After Xenon’s 42.7% Seizure Reduction Data Release
IBRN allocates 3.66% to Xenon Pharmaceuticals, whose shares rallied 16.17% premarket after Phase 3 X-TOLE2 data showed a placebo-adjusted 42.7% median reduction in monthly focal seizures and 54.8% of patients achieved over 50% seizure reduction. Xenon plans an NDA filing in Q3 2026 with peak sales forecast up to $2.6 billion.
1. ETF Exposure and Stock Reaction
The iShares Neuroscience and Healthcare ETF allocates 3.66% of its assets to Xenon Pharmaceuticals, whose shares jumped 16.17% in premarket trading on the back of encouraging Phase 3 X-TOLE2 trial results. This rally contributed to a boost in the ETF’s healthcare segment, reflecting the sensitivity of its performance to key biotech data releases.
2. Phase 3 X-TOLE2 Trial Topline Results
Xenon’s study met its primary endpoint with a placebo-adjusted median monthly focal seizure frequency reduction of 42.7% in the 25 mg cohort, outperforming its Phase 2b data of 34.6%. A key secondary endpoint showed 54.8% of patients in the treatment group achieved at least a 50% seizure reduction, and the company plans an FDA NDA filing in Q3 2026 with peak sales forecast at $2.6 billion.